Telemedicine Growth Strategies: Insights from the WHO European Region

By João L. Carapinha

June 12, 2025

The recently published WHO policy brief, Scaling Up Telemedicine in the WHO European Region, outlines the rapid adoption of telemedicine growth strategies during the COVID-19 pandemic. It identifies systemic barriers to its long-term integration into routine care. Key findings emphasize that 78% of Member States now include telehealth in national strategies. Post-pandemic integration remains uneven due to regulatory inconsistencies, infrastructure gaps, and reimbursement challenges. The report advocates for value-based financing, and standardized clinical guidelines to ensure telemedicine enhances universal health coverage without exacerbating disparities.

Insights into Telemedicine Trends

The pandemic accelerated telemedicine adoption. Teleradiology, telepsychiatry, and general telemedicine became the most utilized services. However, only 53% of countries have defined reimbursement models. Temporary funding measures during COVID-19 risk discontinuation. Clinician acceptance varies, with European family physicians estimating that 20% of future consultations will be remote. Many still prefer in-person care. Structural barriers persist, such as inadequate digital infrastructure in rural areas and interoperability gaps in electronic health records. Telemedicine has demonstrated clinical efficacy in chronic disease management. It reduces hospital readmissions and improves access for marginalized populations when equity-by-design principles are applied.

Economic Implications and Policy Recommendations

The WHO’s findings align with broader trends. Telemedicine can reduce costs for acute care visit, and lower hospitalization rates when paired with remote monitoring. There are funding and infrastructure barriers that require interoperability strategies to align with current clinical and operational practices.

The policy brief calls for value-based reimbursement. These suggest shifting from fee-for-service models to capitation or bundled payments. For example, Germany’s DiGA framework ties reimbursement to demonstrated clinical benefits. France’s PECAN mechanism allows transitional pricing for innovative solutions. Such models incentivize quality but require robust cost-effectiveness data. Health technology assessment (HTA) agencies play critical roles in evaluating digital therapeutics. Fragmented EU regulations complicate cross-border scalability.

Only 33% of Member States have digital inclusion strategies. This risks exclusion for elderly, rural, and low-literacy populations. Telehealth reimbursement parity with in-person care can improve access, as would targeted training for providers to integrate telehealth practices in their daily operations.

Strategies for Sustainable Integration

Sustainable telemedicine integration demands multi-stakeholder collaboration. Policymakers must prioritize interoperable digital infrastructure, leveraging EU-wide standards for data sharing and cybersecurity. Permanent reimbursement frameworks should be informed by value-based pricing. Protocols are essential, including multilingual platforms and low-bandwidth solutions for rural areas. Workforce training programs can address digital literacy gaps, to enable national telehealth scaling.

Failure to address these dimensions risks entrenching telemedicine as a fragmented adjunct rather than a transformative tool. The future of telehealth hinges on aligning clinical, economic, and social imperatives to ensure high-quality care across the European Region. For additional insights, see the comprehensive analysis provided by the World Health Organization here.

Reference url

Recent Posts

The Market Dynamics of Track One Patent Strategy in Pharmaceuticals

By Rene Pretorius

September 26, 2025

In the interconnected landscape of pharmaceutical regulation and innovation, the Track One patent strategy in pharmaceuticals serves as an important component that influences the timing of mar...
Biosimilars Market Trends 2025: Understanding Erosion and Growth
This article explores how biosimilars market trends are transforming the biologics market, making treatments more affordable and reshaping competition. Drawing from a 2022 comparative analysis of US, Germany, and Switzerland markets (2011–2020) [1] and updated 2024–2025 data [2-4] it...
NHS Productivity Gains at Risk: Balancing Innovation and Cost Control

By João L. Carapinha

September 25, 2025

The article by Kate Bowie at the BMJ (linked below) highlights NHS productivity gains, reporting a 2.7% year-on-year increase in hospital efficiency for 2024–25 compared with a 3% rise in costs. This improvement is attributed to measures such as shorter hospital stays, reduced ag...